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 ABSTRACT 
Cutaneous squamous cell carcinoma (SCC) is the second most common form of 
skin cancer in the United States. Using microarrays, we identified lower levels of 
microRNA-1 (miR-1) expression in skin from mice that are susceptible to chemically-
induced skin cancer, compared to skin from resistant mice. Murine SCC cell lines 
show reduced levels of miR-1 compared to normal skin. We hypothesize that the 
decreased expression of miR-1 in susceptible mice and SCC cell lines suggests a 
possible role of miR-1 as a tumor suppressor in skin. To test our hypothesis, we 
transfected a miR-1 precursor into a murine SCC cell line, A5. Upon transfection, we 
measured decreased cell proliferation and migration, and increased apoptosis. 
Using in silico prediction programs, we identified Ets1 as a potential direct target of 
miR-1. We observed decreased Ets1 mRNA and protein expression in A5 cells 
transfected with miR-1. To determine if Ets1 is a direct target of miR-1, we co-
transfected an Ets1 3’UTR luciferase construct and miR-1 into a normal keratinocyte 
cell line, C5N. We observed decreased luciferase expression at 24 hours post-
transfection, suggesting that Ets1 is a direct target of miR-1. In conclusion, miR-1 
appears to target Ets1 and act as a tumor suppressor by increasing apoptosis and 
decreasing proliferation and migration. In future studies, we will characterize the role 
of Ets1 in SCC cell proliferation, apoptosis, and migration, and identify other targets 
and tumor-related phenotypes associated with miR-1. 
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CHAPTER 1 
INTRODUCTION 
1.1. Cutaneous Squamous Cell Carcinoma (SCC) 
 As the largest organ in the human body, the skin serves a primary function to 
protect internal tissues and organs from detrimental environment effects. The skin 
consists of two layers, the dermis and epidermis. The dermis provides mechanical 
support whereas the purpose of the epidermis is largely protection. Five layers of cells 
are combined to form the epidermis, which include the following in order from deep to 
superficial: stratum basale, stratum spinosum, stratum granulosum, stratum lucidum, 
and stratum corneum. Keratinocytes begin to differentiate in the basal layer and 
differentiate outward towards the surface of the skin. Cells fully differentiate upon 
reaching the stratum corneum [1]. 
 Nonmelanoma skin cancer (NMSC) results from tumorigenesis of the epidermis 
and includes basal cell carcinoma (BCC) and squamous cell carcinomas (SCC). Rogers 
et al. estimates that in the United States, there are nearly 3,500,000 NMSCs and 
greater than 2,100,000 individuals treated each year. Further, recent studies show that 
around 1,000,000 new NMSCs arise in the U.S. each year, and there was a dramatic 
76.9% increase in NMSC treatment procedures for the Medicare population between 
1992 and 1996  [2]. Common treatment for NMSCs is surgical removal, and costs of 
actinic keratoses and NMSCs in the U.S. combined exceed $3.5 billion each year [3]. 
 Cutaneous squamous cell carcinoma  (SCC) is the second most common form of 
skin cancer with approximately 700,000 diagnoses made each year [4]. Actinic 
keratosis, pre-cancerous keratinocytes in situ, commonly precedes the development of 
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SCC, and occurs on the outermost layer of the epidermis. SCC is caused by ultraviolet 
radiation exposure from the sun and most commonly occurs on the arms, legs, nose, 
and ears [5]. Other SCC risk factors include: old age, smoking, human papilloma virus, 
infection, and chronic inflammation of the skin. Also, men are at a higher risk of 
obtaining SCC than women. Tumors appear as raised, ulcerous, papules [6]. 
  
1.2. MicroRNAs 
 MicroRNAs are small, ~25 nucleotide strands of RNA that are thought to inhibit 
gene expression via translational inhibition [7].  The mechanism by which this occurs 
first begins with transcription of the 1-3 kb primary microRNA (pri-miR) by RNA 
polymerase II [8]. The pri-miR is then processed by the enzyme DROSHA to a 70 bp, 
stem-loop precursor microRNA (pre-miR) which is exported from the nucleus to the 
cytoplasm by Exportin-5/RanGTP complex [9,10]. In the cytoplasm, the pre-miR is 
cleaved by DICER to the mature, ~22 nucleotide, microRNA (miR). The miR then 
complexes with the RISC protein complex and binds to a complimentary seed region (7-
9 bp) in the 3’ untranslated region (3’UTR) of a target gene mRNA where it will cause 
degradation if it is exactly complimentary or otherwise induce translational repression 
through steric hindrance [11]. However, recent studies suggest that microRNAs may 
also bind to the 5’UTR, other microRNAs, promoter regions, and ribonucleoproteins 
[12]. MiRs have been shown to act as tumor suppressors or oncogenes, and are 
thought to regulate about 30% of the human genome [12,13,14,15]. 
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1.3 MicroRNA-1 (miR-1) 
  MicroRNA-1 (miR-1) was identified as a cardiac and skeletal muscle specific 
microRNA (myomiR) that falls into a family of six other miRs [16,17,18,19].  It has been 
shown to help regulate skeletal muscle and cardiomyocyte progenitor cell proliferation 
and differentiation [20,21,22]. MiR-1 has also been shown to be pro-apoptotic in skeletal 
muscle and cardiomyocytes [23,24]. Further, miR-1 is down-regulated in human lung, 
liver, and skeletal muscle cancer where decreased cell growth and proliferation is 
observed upon introduction of miR-1 into the cancer cell lines [25,26,27]. 
 In previous studies performed by other members of the Toland lab, a microarray 
revealed decreased microRNA-1 (miR-1) expression in a mouse strain susceptible to 
chemically induced [12-dimethylbenz(a)anthracene (DMBA) and 2-O-tetradecanoyl-
phorbol-13-acetate (TPA) induced] SCC compared to a mouse strain that is resistant 
[28]. These results were further confirmed via quantitative real-time PCR indicating a 2-
fold decrease of miR-1 expression in the skin of susceptible mice compared to resistant 
mice. Additionally, the A5 SCC cell line shows greatly reduced (undetectable) levels of 
miR-1 when compared to the C5N normal keratinocyte cell line. The inverse correlation 
of expression in mice susceptible to cutaneous SCC compared to those resistant 
suggests that miR-1 may play a role in tumorigenesis. 
 
1.4  Ets1 
Ets1 is a transcription factor oncogene shown to be involved in regulation of the 
tumorigenesis promoting EGFR-Ras-MEK1/2 MAPK pathway [29,30,31,32].   Ets1 is 
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also known to fuse with the E26 avian leukaemia virus c-myb proto-oncogene which is 
also an important causation of tumorigenesis [33,34].  
Specifically, Ets1 has been shown to play a role in SCC tumor development and 
progression [6,35,36]. Ets1 acts as a SCC tumor promoting gene by inducing SCC cell 
proliferation in transgenic mice over-expressing Ets1 [35].  Studies show that Ets1 
regulates genes important in apoptosis, angiogenesis, migration, invasion, and 
specifically, matrix metalloproteinases which enhance cell migration [36,37,38]. In 
addition, it is over-expressed in human SCC malignancies [37,39,40,41,42,43].  
 
1.5 Study Rationale and Hypothesis 
There are three parts to this study. 
1. To test the role of miR-1 as a tumor suppressor gene 
2. To determine if Ets1 is a direct target of miR-1 as well as the specific phenotypes 
associated with Ets1. 
3. To determine the mechanism of miR-1 down-regulation in SCC.  
 By definition, a gene is considered a tumor suppressor if its loss or inactivation 
results in neoplastic growth irregularities [44]. When present at normal expression 
levels, tumor suppressor genes help regulate normal cell processes, but when inactive 
a cell can experience phenotypes such as uncontrollable proliferation, decreased 
apoptosis, de-regulated cell cycles, increased migration, increased invasion, or 
increased metastasis. These phenotypes lead to tumorigenesis. The decreased 
expression of miR-1 in mice susceptible to cutaneous squamous cell carcinoma 
compared to resistant mice, alongside data from previous studies supporting a role of 
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miR-1 in important tumor phenotypes (e.g. proliferation, apoptosis, and migration) led to 
the hypothesis. The hypothesis of this thesis is that miR-1 may act as a tumor 
suppressor in cutaneous squamous cell carcinoma by down-regulating Ets1.  
 Our in silico studies show that Ets1 is a predicted target of miR-1. Ets1 is also 
implicated as an oncogene. Confirmation of the means by which miR-1 regulates Ets1 
expression provides us with a better understanding of the mechanism by which miR-1 
acts as a SCC tumor suppressor. Down-regulation of Ets1 could occur by miR-1 binding 
to the Ets1 3’UTR and inhibiting translation.  (We assume that the RISC proteins 
subsequently form a complex with the microRNA when the microRNA binds to the 
3’UTR.) However, down-regulation of Ets1 expression via miR-1 could also occur if 
miR-1 down-regulates a gene responsible for up-regulation of Ets1, such as a 
transcription factor. Experimentation was necessary to differentiate between these 
previous two possible mechanisms of regulation. A specific step of the mechanism 
could be exploited by future studies to investigate and possibly develop potential SCC 
therapeutics.  We hypothesize that miR-1 acts as an SCC tumor suppressor by directly 
reducing expression of the transcription factor oncogene, Ets1, via binding to the Ets1 
3’UTR.  
 According to in silico prediction programs, www.microRNA.org and 
www.targetscan.org, there are three binding sites for miR-1 on the Ets1 3’UTR.  The 
accepted mode of microRNA regulation of target genes in various cancers is via direct 
binding of the microRNA to the 3’UTR of the target gene. Studies have shown that even 
1-2 microRNA binding sites on the 3’UTRs of target genes is sufficient for down-
regulation, which suggests three binding sites may be more than sufficient in our study 
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[25,41,45].However, we wanted to confirm that miR-1 is directly binding to the 3’UTR 
rather than indirectly regulating another intermediate that can bind to the 3’UTR, such 
as another microRNA. 
 Finally, differential expression of microRNAs in tumor versus normal tissue is 
often associated with epigenetic alterations such as DNA methylation or chromatin 
silencing [26,46,47,48,49,50,51]. Specifically, miR-1 expression has been shown to be 
suppressed in human liver and lung cancer via histone-silencing, and its expression 
was rescued upon treatment of cancer cells with a histone-deacetylase inhibitor, 
trichostatin A (TSA). MiR-1 has also been shown to be suppressed in human liver 
cancer by Methylation, and its expression was rescued upon treatment of the cells with 
a de-Methylating agent, 5-Azacytidine (5-AzaC). This leads us to investigate these 
forms of miR-1 down-regulation in cutaneous SCC.   
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Cell Lines  
Our experiments are performed using murine cell lines. In particular, we used the 
A5 SCC cell line and C5N normal keratinocyte cell line. The A5 cell line was directly 
derived from a mouse SCC tumor, and the C5N cell line was directly derived from 
mouse normal skin. Both cell lines are immortalized. Cells were grown in Dulbecco’s 
modifications of Eagle’s medium (DMEM, Cellgro) supplemented with 10% fetal bovine 
serum (GIBCO, Invitrogen) and 5% penicillin streptomycin (Invitrogen). Cells were 
trypsinized with 0.05% trypsin and 0.5 mM EDTA in HBSS with sodium bicarbonate, 
calcium, and magnesium.  
 
2.2 Transfections 
All transfections were performed using Lipofectamine 2000. The transfections for 
measuring proliferation, apoptosis, migration, and miR-1 target gene expression were 
performed according to the Lipofectamine 2000 protocol in a final volume of 13 mL of 
OPTI-MEM in a 10 cm dish (Invitrogen). Co-transfections were performed per 
manufacturer’s recommended protocol as the other transfections, with the co-
transfected oligonucleotides transfected together with no adjustments in volumes as 
specified by the original transfection protocol.  130,000 A5 cells were plated one day 
prior to transfection in a 10 cm dish. Cells were transfected at 50% confluency. For each 
dish, 600 pmol of miR-1 precursor molecule (Ambion), 600 pmol of scrambled precursor 
negative control (Ambion), and 500 ng of pCMV Ets1 construct lacking the Ets1 3’UTR 
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(donated as a gift from the laboratory of Michael Ostrowski) were transfected into A5 
cells. For brevity, the miR-1 precursor molecule, scrambled negative control precursor 
microRNA molecule, and Ets1 pCMV construct lacking the 3’ UTR will be referred to as 
miR-1, negative control, and Ets1 respectively throughout the rest of manuscript. 
 
2.3 Cell Proliferation 
One day post-transfection with either a scrambled precursor negative control or 
precursor to miR-1, A5 cells in the 10 cm dish were trypsinized, and 2,000 cells were 
replated in quadruplicate into a 96 well dish. Proliferation was measured at 24, 48, and 
72 hours post-transfection using the MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) Cell Proliferation Kit I according to manufacturer’s 
instructions (Roche). The cells were solubilized four hours after the addition of the MTT 
reagent using the kit’s provided solubilization reagent. The solution was then incubated 
for 24 hours, and absorbance was then measured at 550 nm using a 
spectrophotometer.   
 
2.4 Apoptosis 
One day post-transfection with a scrambled precursor negative control or a 
precursor to miR-1, A5 cells in the 10 cm dish were trypsinized, and 2,000 cells were 
replated in triplicate into a 96 well dish. Apoptosis was measured at 24, 48, and 72 
hours post-transfection using a Caspase-Glo 3/7 Assay according to manufacturer’s 
instructions (Promega). Samples were incubated with the caspase substrate for 1 hour. 
Caspase 3/7 activity was then measured using a luminometer.   
15 
 
 2.5 Cell Migration 
At 60 hours post-transfection, A5 cells transfected in a 10 cm dish with a 
scrambled precursor miR negative control or precursor to miR-1 were trypsinized, and 
30,000 cells were replated in triplicate into the upper chamber of the 8.0 um-translucent 
Transwell (Greiner Bio One). Prior to plating the cells, the Transwell was coated with 
fibronectin (5 ng/uL). Epidermal growth factor (10 ng/mL) was added to the lower 
chamber. Cells migrated for 12 hours after which they were fixed in 1% gluteraldehyde 
and stained with crystal violet. Cells were solubilized with Sorenson’s buffer, after which 
absorbance was measured at 595 nm using a spectrophotometer.  
 
2.6 Target Genes 
Predicted targets of miR-1 were identified using the in silico prediction programs, 
www.microRNA.org and www.targetscan.org. Predicted targets are identified based on 
the degree of complimentary alignment between microRNA-1 and the 3’UTR binding 
site on the target gene’s mRNA. The greater the degree of complimentary alignment, 
the higher score a target receives, and then the more likely it is that the gene may be a 
predicted target. From the list of predicted targets provided, specific genes were chosen 
to focus on based on alignment scores and literature review describing the function 
these genes have been shown to play in cellular processes. After selecting the 
predicted targets, there mRNA and protein expression was measured post miR-1 
transfection using SYBR Green quantitative real-time PCR and western blotting 
respectively. 
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 2.7 Ets1 3’UTR Luciferase Reporter Assay 
A murine Ets1 3’UTR insert containing three predicted miR-1 binding sites was 
cloned into a pGL3 Firefly luciferase reporter vector (Luc-Ets1 3’UTR Promega). Two 
base pair substitutions were generated in each miR-1 binding site in the Ets1 3’UTR 
using site-directed mutagenesis (Luc-Ets1 3’UTR-M, Stratagene). Mutated binding sites 
were generated to avoid creation of new microRNA binding sites as verified by 
www.patrocles.org. 
C5N normal keratinocyte cells were plated in triplicate into a 12-well dish at 24 
hours prior to transfection. At 70% confluency, 0.10 ug Luc-Ets1 3’UTR and Luc-Ets1 
3’UTR-M were each co-transfected with 10 pmol of a scrambled precursor negative 
control miR or miR-1 into each well. 0.10 ug of PRL-TK (TK-driven Renilla luciferase 
vector) was also transfected into each well. Transfections were performed using 
Lipofectamine 2000 according to protocol (Millipore).  Luciferase expression was 
measured using a luminometer at 24 hours post-transfection and Firefly luciferase 
expression was normalized to Renilla expression.  
 
2.8 De-methylation Studies 
A5 SCC cells were plated in triplicate into a 12-well dish 24 hours prior to drug 
treatment. At 70% confluency, cells were treated with 5-azacytidine (5-AzaC; 5uM or 10 
uM) for 48 hours, trichostatin A (TSA; 0.3 uM) for 24 hours, or a combination of 5-AzaC 
treatment for 48 hours and TSA treatment for 24 hours. RNA was harvested post-
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transfection and miR-1 expression was measured via Taqman quantitative real-time 
PCR.  
 
2.9 Chromatin Immunoprecipitation 
A chromatin immunoprecipitation assay was carried out on DNA/chromatin 
complexes isolated from A5 SCC and C5N normal keratinocyte cell lines according to 
protocol (Millipore). 130,000 cells were 70% confluent and cross-linked with 
formaldehyde (Immunoprecipitation was performed using the histone H3 dimethyl K9 
antibody (Abcam; ab1220). The miR-1 promoter region was amplified using miR-1 
promoter primers from Integrated DNA Technologies (Table 1).  The amplified DNA was 
run on a 1% agarose gel with ethidium bromide, and the bands were visualized using 
UV radiation.  DNA from a no-antibody control was used for normalization for loading 
control. Semi-quantification to measure pixel intensity was performed using Alpha 
Imager software.  
 
2.10 Quantitative-PCR 
RNA was extracted from 24, 48, and 72 hours transfections using RiboZol 
Extraction Reagent (AMRESO). MicroRNA cDNA was generated from the extracted 
RNA according to manufacturer’s protocol (Applied Biosystems). Target gene cDNA 
was generated from extracted RNA using the I-Script kit according to manufacturer’s 
protocol (BioRad). Transfection efficiency was verified via measuring miR-1 and Ets1 
expression at 24, 48, and 72 hours post-transfection using quantitative real-time PCR 
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(qPCR). mRNA expression of potential miR-1 target genes were also measured using 
qPCR.  
Taqman qPCR was performed in triplicate according to manufacturer’s protocol 
to measure miR-1 expression (Applied Biosystems). MiR-1 expression was presented 
as a percent relative expression to sno202 expression using the ΔCT equation 
(equation: (2X)*100 where x= control gene expression-target gene expression). Probes 
were obtained via Applied Biosystems. 
SYBR green qPCR was peformed in triplicate according to manufacturer’s 
protocol and was used to measure Ets1 and other target gene expression (Integrated 
Techonologies). Primers were designed using Integrated DNA Technologies. Ets1 and 
other potential miR-1 targets were normalized to L19 expression using the ΔCT 
equation (equation (2X)*100 where x= control gene expression-target gene expression). 
 
2.11 Western Blotting 
Protein was extracted from 72 hours transfections via solubilization of the cells in 
RIPA buffer (50 mM Tris base pH 8, 150 mM NaCl, 1% NP40, 0.10% SDS) and 
subsequent removal of the supernatant (30 uL). Equal amounts of protein (30 ug each) 
were separated by 10% SDS-PAGE and then transferred to nitro-cellulose membrane. 
The membranes were blocked with a buffer containing 5% nonfat milk in phosphate-
buffered saline with 0.05% Tween 20 for 30 min and incubated overnight with a 1:5000 
dilution of Ets1 primary antibody (provided as a gift by the laboratory of Michael 
Ostrowski). After 3 washes with phosphate-buffered saline with 0.05% Tween 20, the 
membranes were incubated with a 1:10,000 dilution of an anti-rabbit secondary 
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antibody for 2 hours α-tubulin (Santa Cruz Biotechnology) was used as a loading 
control.  
2.12 Calculations and Statistical Analysis 
Averages and standard deviations were determined for experimental and 
negative control variables using Microsoft Excel. A two-tailed student’s t-test was used 
to determine significance. Differences between variables were considered significant if 
p<0.05. 
 
2.13 Primers: Table 1 
 
Amplified DNA Forward Reverse
miR-1 Promoter 5’ CTG T CC AGG TAA GCC CTT TGA TTC 3’ 5’ GCA GAA CAA TGC CAA CAG GGA CA 3’
Ets1 5’ TGT ATG AGT GGA GCA GCA CTG TGT 3’ 5’ AGG TAG GGT CTC CAT TAA CCT 3’
Met 5’ AAC GGG TAT TGG GAA GAC CCT GAA 3’ 5’ ATC CCG TCT AAC AGG AAG AAG GCT 3’
Bag4 5’ ACT CCA CGG AAG T TC CAA ACA CCT 3’ 5’ T TC CAG GGT TCT GTG AAG CAG GAT  3’
Ptk9 5’ TTC CAG GCT  TTG GAG AAG GT G AGT 3’ 5’ AGT CTC CTT  CGT  GGG AAT GCT TGT 3’
Ets1 3’UTR 5’ GTA CGT ACA CTA GTA TCC CTT CCA CTG T AT AGC TGC CT 3’
5’ GCA TGC ATC CGC GGC GCT ACA TCT CTA 
AGC T AC CTC AGT TC 3’
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
TABLE 1. Primer sets used for PCR amplification throughout experimentation. The miR-1 promoter was 
amplified for ChIP experimentation. Ets1, Met, Bag4, and Ptk9 were amplified in SYBR Green qPCR. The 
Ets1 3’UTR was amplified for a cloning insert. 
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RESULTS 
 
3.1 MiR-1 Reduces Cell Proliferation 
To determine if miR-1 affects cell proliferation, miR-1 and a scrambled precursor 
miR negative control (NC) were transfected into A5 cells, and cell proliferation was 
measured at 0, 24, 48, and 72 hours post transfection via an MTT assay (Figure 1).  
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0 24 48 72
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m
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Effect of miR-1 on Cell Proliferation
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miR-1
FIGURE 1. Cell proliferation (OD 550) was measured via an MTT assay at 0, 24, 48, 
and 72 hours post transfection in A5 cells transfected with miR-1 (black, square) and 
scrambled precursor miR negative control (gray, triangle, NC). Proliferation at each 
time point was measured in quadruplicate. *p < 0.0001. 
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A significant decrease in cell number was observed at 72 hours post-transfection 
in miR-1 transfected cells compared to the NC (1.70 fold decrease, n=4, p < 0.0001; 
Figure 1). A significant decrease in growth rate was also observed from 48 to 72 hours 
post-transfection in miR-1 transfected cells compared to the NC (2.20 fold decrease, 
n=4, p <0.0001) Similar results were observed in a replicate experiment.  These results 
suggest miR-1 reduces cell proliferation.  
 
3.2 MiR-1 Induces Apoptosis 
 
To determine if miR-1 induces apoptosis, miR-1 and a scrambled precursor miR 
negative control (NC) were transfected into A5 cells, and the degree of apoptosis was 
measured at 24, 48, and 72 hours post-transfection using a Caspase-Glo 3/7 assay 
(Figure 2). A significant increase in apoptosis was observed at 48 and 72 hours post 
transfection in miR-1 transfected cells compared to the NC (48 hour: 1.61 fold increase; 
n=3; p < 0.0001 and 72 hour: 2.07 fold increase; n=3; p < 0.05). These results suggest 
miR-1 induces apoptosis, which, in part, may account for the observed decrease in cell 
proliferation at 72 hours post-transfection. Subsequent experiments did not show 
significant differences in apoptosis between miR-1 and NC transfected cells at 48 and 
72 hour post-transfection. Further experimentation must be performed to clarify the role 
of miR-1 in apoptosis.  
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3.3 MiR-1 Reduces Cell Migration 
To determine if miR-1 decreases cell migration, miR-1 and a scrambled 
precursor miR negative control (NC) were transfected into A5 cells. At 60 hours post-
transfection, the cells were placed were subject to a Transwell migration assay in which 
the cells were allowed to migrate through a fibronectin-coated membrane for 12 hours. 
Crystal violet staining was performed and the degree of migration was assessed using 
spectrophotometry (Figure 3). Cells transfected with miR-1 experienced a 1.30 fold 
decrease in migration compared to cells transfected with a negative control (n=3, p< 
0.05). 
FIGURE 2. Apoptosis (~caspase 3/7 activity) was measured via a Caspase-Glo 3/7 assay at 
24, 48, and 72 hours post-transfection in A5 cells transfected with miR-1 (black) and a 
scrambled precursor miR negative control (gray, NC). Apoptosis was measured in triplicate. 
**, p < 0.0001.  *, p < 0.05. 
NC
miR-1
*
**
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3.4 MiR-1 Down-regulates Various Target Genes 
Using the in silico predication programs, www.microRNA.org and 
www.targetscan.org, various predicted miR-1 targets were identified based on 
complementary alignment of miR-1 to the target gene’s 3’UTR (Table 2). Initially, the 
genes Ets1, Met, Bag4, Sp1, Taok1, Trp53, and Zfp148 were chosen because they had 
the highest number of miR-1 binding sites in their 3’UTR.  From this list of targets, Ets1¸ 
Met, and Bag4 were chosen to perform expression studies based on the number of 
binding sites and literature review on their role in cellular processes. Ets1 (E26 avian 
leukemia oncogene 1) is a transcription factor oncogene over-expressed in cutaneous 
0
2
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8
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12
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D
 (5
95
)
Effect of miR-1 on Migration
*
NC
miR-1
FIGURE 3. Migration (OD 595) was measured via a Transwell migration assay and subsequent 
crystal violet staining at 72 hours post-transfection in A5 cells transfected with miR-1 (black) and 
those transfected with a scrambled precursor miR negative control (grey, NC). n=3, *, p < 0.05. 
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SCC thought to regulate genes important in apoptosis, cell proliferation, and migration 
[15,36,37,38,39,41,52]. Met encodes c-Met, which is has been shown to be implicated 
in the progression of various cancers and has also been shown to be a target of miR-1 
in rhabdomyosarcoma. As a kinase, c-Met activates proteins via phosphorylation. 
[27,52,53]. Bag4 (Bcl-2 associated athanogene 4) is an anti-apoptotic co-chaperone for 
Bcl-2 that has been shown to contribute to progression of breast, pancreatic, gastric, 
and ovarian cancers [54,55,56,57,58] . Ptk9 is a known target of miR-1 used as a 
positive control. Ets1, Met, and Bag4 all have greater than one miR-1 target site on their 
3’UTR.  Also, all have predicted target sites in Homo sapiens, and  both Ets1 and Met 
have one conserved target site between human and mice.  
Targ et
# Target 
Sites-Mus
mu sculu s
# Targ et  
Sites-Hom o 
sap ien s
# Conserved 
Target Sites
Fo ld Decrease 
mRNA Expression 
(48 HR)
F old Decrease 
mRNA Exp ression 
(72 HR)
Fo ld  Decrease 
Protein Expression 
(72 HR)
Ets1 3 2 1 1.1 1.71*** 8.75
Met 2 2 1 2.45** 1.66** n/a
Bag4 3 1 0 0.93 2.02 n/a
Ptk9 1 1 0 3.16*** 1.98*** n/a
Potential m iR-1 TargetsPotential miR-1 Targets 
TABLE 2. Two in silico prediction program, www.microRNA.org and www.targetscan.org were used to identify 
various target genes of miR-1, the number of miR-1 target sites on their 3’UTR in M. musculus and H. sapiens, as 
well as the number of conserved target sites between the two species. Ptk9 is a known miR-1 target used as a 
positive control.  MiR-1 and a scrambled precursor miR negative control (NC) were transfected into A5 cells, and 
the fold decrease in mRNA and protein expression between miR-1 transfected and NC transfected cells was 
calculated after performing quantitative real time PCR and western blotting respectively. MRNA expression was 
measured in triplicate. Protein expression was measured in one sample. n=3, ***, p <0.002. **, p <0.02. 
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FIGURE 4. FIGURE 4. Ets1 (A), Met (B), Bag4 (C), and Ptk9 (D) mRNA expression were measured via SYBR Green 
qPCR at 48 and 72 hours post-transfection in cells transfected with either a scrambled precursor miR negative control (NC; 
black) or miR-1 (grey). n=3, ***, p <0.002. **, p <0.02.  
 
Translational Repression of Ets1 via miR-1 
Ets1 
 
α -tubulin  
Mock miR-1 NC 
 
FIGURE 5. Ets1 protein expression was measured via western blotting at 72 hours post-transfection. Ets1 expression is 
decreased in A5 cells transfected with miR-1 compared to cells transfected with no RNA (mock) or a negative control (NC), 
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Upon transfection of miR-1 and a scrambled precursor miR negative control (NC) 
into A5 cells, the expression of the target genes was measured using quantitative real 
time PCR and western blotting (protein has currently only been measured for Ets1). A 
significant decrease in Ets1 mRNA expression is observed at 72 hours post-transfection 
in cells transfected with miR-1 compared to those transfected with the NC (Figure 4; 
n=3, p<0.002). Although significance levels could not be calculated because n=1, Ets1 
protein expression was also shown to be decreased dramatically at 72 hours post 
transfection in cells transfected with miR-1 compared to those transfected with the NC 
(Figure 5).  A significant decrease in Met mRNA expression is observed at both 48 and 
72 hours post-transfection in cells transfected with miR-1 compared to those transfected 
with the NC (Figure 4; n=3, p<0.02). Bag4 mRNA expression was not significantly 
decreased by miR-1, but it could still be a target of translational repression. Finally, Ptk9 
mRNA expression is decreased at both 48 and 72 hours post-transfection in cells 
transfected with miR-1 compared to those transfected with the NC ( Figure 4; n=3, 
p<0.002). Based on inverse correlation of expression, these data suggests Ets1 and 
Met are both potential targets of miR-1 in cutaneous SCC.   
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3.5 MiR-1 Regulates Ets1 Expression via the 3’UTR 
To determine if miR-1 regulates Ets1 via the 3’ untranslated region (3’UTR), we 
created two luciferase constructs containing either the Ets1 3’UTR (Luc-Ets1 3’UTR) or 
the Ets1 3’UTR with mutated miR-1 binding sites (Luc- Ets1 3’UTR-M). We performed 
site-directed mutagenesis to alter two base pairs in each of the miR-1 binding sites in 
the Ets1 3’UTR. The mutations did not confer any more microRNA binding sites (Table 
3). The constructs were co-transfected with either a precursor to miR-1 or a scrambled 
precursor miR negative control (NC). 
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FIGURE 6. The Ets1 3’UTR and the Ets1 3’UTR with mutated miR-1 binding sites (Ets1 3’UTR-M) were 
each cloned into a luciferase construct. The constructs were then co-transfected with either a negative 
control (NC) or miR-1 and luciferase activty was measured.  Ets1 3’UTR was created via site-directed 
mutagenesis. n=3 , *p < 0.007. This experiment was performed by Jessica Fleming. 
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A 3.2 fold decrease in luciferase expression was observed in cells co-transfected 
with Luc-Ets1 3’UTR and miR-1 compared to those co-transfected with a NC, which 
suggests miR-1 regulates Ets1 through the Ets1 3’UTR (Figure 6; n=3, p < 0.007). No 
significant difference in luciferase expression was observed in cells co-transfected with 
Luc-Ets1 3’UTR-M and miR-1 compared to those co-transfected with Luc-Ets1 3’UTR-M 
and a NC. This suggests miR-1 regulates Ets1 expression via direct binding to the 
predicted miR-1 binding sites. 
miR-1
Binding Site 
in the Ets1
3’UTR
Site 1 Site 2 Site 3
NORMAL 5’ ACUCC—CACAUUCCc 3’ 5’ ACAUUCC 3’ 5’ CUUACGUACAUUCC 3’
MUTATED 5’ACUCC—CACAUCUCc 3’ 5’ ACACUCC 3’ 5’ CUUACGUACUCUCC 3’
 
TABLE 3. Luc-Ets1 3’UTR-M was created via site-directed mutagenesis of the three miR-1 binding sites. 
Two base pairs were mutated in each of the normal binding sites. The new, mutated binding sites did not 
confer new microRNA binding sites.  
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3.6 Ets1 is Unable to Rescue the Effect of miR-1 on Cell Proliferation  
MiR-1, an Ets1 promoter cyclomegalovirus construct lacking the 3’UTR (Ets1), 
and a scrambled precursor negative control (NC) were transfected into A5 cells to 
determine if Ets1 is responsible for the increased cell proliferation in cells lacking miR-1. 
Ets1 and miR-1 (Ets1 + miR-1) were also co-transfected into A5 cells. Cell proliferation 
was measured via an MTT assay at 24, 48, and 72 hours post-transfection. A significant 
increase in cell number was observed at 72 hours post-transfection in cells transfected 
with Ets1 compared to cells transfected with either a NC, Ets1+ miR-1, or miR-1.  
[Figure 7; Ets1:NC, 1.81 fold increase; Ets1:(Ets1 + miR-1), 2.44 fold increase; 
Ets1:miR-1, 2.04 fold increase; n=4; p<0.0001]. A significant increase in growth rate 
was also observed from 48 to 72 hours post-transfection in cells transfected with Ets1 
compared to cells transfected with either a NC, Ets1+miR-1¸or miR-1. [Figure 7; 
Ets1:NC, 1.88 fold increase; Ets1:(Ets1 + miR-1), 3.11 fold increase; Ets1:miR-1, 2.75 
fold increase; n=4; p<0.0001].  
Although a significant difference in cell number was not observed for cells 
transfected with a miR-1 or Ets1+miR-1 compared to cells transfected with a negative 
control at 72 hours post-transfection, a significant decrease in growth rate was observed 
for cells transfected with a miR-1 or Ets1+miR-1 compared to cells transfected with a 
NC from 48 to 72 hours post-transfection. [Figure 7; (Ets1+ miR-1): NC, 1.73 fold 
decrease, n=4, p<0.02; miR-1: NC, 1.50 fold decrease, n=4, p <0.01]. It appears that 
Ets1 acts to increase cell proliferation and growth in the absence of miR-1, but cannot 
rescue the affects of decreased proliferation growth rate induced by miR-1.Yet, as 
confirmed in an earlier MTT assay, the presence of miR-1 still decreases the growth 
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rate of A5 cells from 48 to 72 hours post-transfection. Overall, these results suggest 
miR-1 may affect proliferation and growth rate by down-regulating target proteins other 
than Ets1.   
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FIGURE 7. MiR-1 (dashed square), an Ets1 PCM construct lacking the 3’UTR (square, Ets1), 
and a scrambled precursor miR negative control (diamond, NC) were transfected into A5 cells. 
Ets1 and miR-1 (triangle, Ets1+miR-1) were also co-transfected into A5 cells. Cell proliferation 
was measured via an MTT assay at 24, 48, and 72 hours post-transfection.  Proliferation at each 
time point was measured in quadruplicate. *, p < 0.0001.    
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3.7 Methylation is not Responsible for Down-regulating miR-1  
To determine if methylation was responsible for the differential miR-1 expression 
in tumor cell lines, we treated A5 cells with 5-Azacitidine (5-AzaC), trichostatin A (TSA), 
or a combination of both (5-AzaC + TSA). RNA was isolated from cells treated with 5-
AzaC at 48 hours post-transfection and cells treated with TSA or 5-AzaC + TSA at 24 
hours post-transfection. MiR-1 expression was measured via qPCR, and no significant 
change in expression was seen in treated versus non-treated cells (Figure 8).   
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FIGURE 8: Relative miR-1 expression was measured via Taqman Real Time PCR in A5 SCC 
cells after treatment with either 5-azaC, TSA, or a combination of the two drugs. Treatments 
were performed with 5-azaC for 48 hours at 5 uM and 10 uM concentrations (A), TSA for 24 
hours at 0.3 uM concentration (B), and a combination of the two drugs with 5-azaC for 48 hours 
at 5 uM and 10 uM concentrations and TSA for 24 hours at 0.3 uM concentration (C). MiR-1 
expression was not significantly different between treated and untreated cells. These 
experiements were performed by Jessica Fleming. 
3.8 Chromatin Silencing is Not Responsible for Down-regulating miR-1 
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  B.  
Because the mouse promoter for miR-1 contains no CpG islands, segments of 
DNA where methylation is likely, we wanted to determine if histone silencing might be 
occurring in the absence of DNA methylation. A chromatin immunoprecipitation (ChIP) 
assay was performed using DNA/protein complexes isolated from A5 and C5N cell 
lines. Semi-quantitative analysis of the ChIP product revealed histone silencing of the 
miR-1 promoter, but with no significant difference in A5 cells compared to C5N (Figure 
9). 
FIGURE 9. A ChIP assay was performed on A5 and C5N cells to detect chromatin-silencing 
in the miR-1 promoter region. A5 and C5N chromatin/DNA complexes were isolated via H3K9 
specific antibody (ab) from which the miR-1 promoter region was amplified through PCR (A). 
Semi-quantification of the ChIP assay PCR product was performed to determine the relative 
degree to which A5 and C5N cell lines are chromatin-silenced. To amplify the miR-1 promoter 
region, a PCR was performed with 20 ng of the A5 and C5N DNA retrieved after the ChIP 
assay, and then the PCR product band intensities were measured via computer analysis. 
Minimal difference in chromatin silencing between A5 and C5N cell lines was observed (B). 
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CHAPTER 4 
DISCUSSION 
We hypothesized that miR-1 acts as a tumor suppressor in cutaneous squamous 
cell carcinoma by affecting various phenotypes including cell proliferation, apoptosis, 
and migration and that it also down-regulates the transcription factor oncogene, Ets1. 
Further, we tested for methylation and chromatin silencing in the miR-1 promoter region 
to determine the mechanism for down-regulation of miR-1 in SCC. In summary, we had 
three aims to our study: 
1. Determine the phenotypes associated with miR-1 in SCC. 
2. Verify Ets1 was a direct target of miR-1, and that miR-1 down-regulated 
Ets1 via binding to the 3’UTR. 
3. Determine the mechanism of down-regulation of miR-1 in SCC. 
 
4.1 MiR-1 Affects Tumor Suppressor Phenotypes 
 From our results, miR-1 transfection results in a decrease in cell number and 
migration at 72 hours as well as a dramatic decrease in growth rate between 48 and 72 
hours post-transfection in cells transfected with miR-1 compared to those transfected 
with a scrambled precursor miR negative control (NC). Furthermore, apoptosis was also 
significantly increased at 48 and 72 hours post-transfection in cells transfected with 
miR-1 compared to those transfected with the NC. This suggests that apoptosis, in part, 
may be decreasing cell proliferation by inducing apoptosis, and other studies have 
shown miR-1 to act similarly  in lung, liver, and skeletal muscle cancers [25,26,27]. 
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Cell death may be responsible for the decreased number of cells; however, it is 
also possible that miR-1 may be regulating expression of proteins important in cell cycle 
regulation. In this case, cells may not necessarily be undergoing apoptosis, but dividing 
less rapidly.  Both apoptosis and cell cycle inhibition could be inhibited by miR-1. To 
determine if cell cycle inhibition contributes to the decrease in proliferation, it will be 
necessary to transfect cells with miR-1 and perform flow cytometry to determine what 
stage of the cell cycle (e.g. G0, G1, G2, S, or M) the majority of cells are in compared to 
the NC. 
 
4.2 Ets1 is a target of miR-1 
 
After identifying Ets1 and Met as potential targets of miR-1 using the in silico 
prediction programs, as well as literature review, expression studies revealed that both 
genes are down-regulated at the mRNA level upon introduction of exogenous miR-1. 
Further, Ets1 is significantly down-regulated at the protein level upon introduction of 
exogenous miR-1, which coincides with a commonly accepted mechanism of microRNA 
regulation via translational inhibition [11]. 
Not only do we confirm miR-1 down-regulates Ets1, but we have shown it does 
so by directly binding to the 3’UTR. This has major implications as it provides an 
approach for potential SCC therapies using the miR-1 pathway. Although it appears that 
Ets1 does not affect proliferation, if we can show preferentially knocking down Ets1 
induces other phenotypes (potentially increased apoptosis, and decreased migration) as 
miR-1, then therapies could be focused not necessarily on reintroducing miR-1 but by 
introducing an Ets1 siRNA. Although microRNA therapy has many advantages, 
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microRNAs have the capability to down-regulate many genes which could lead to 
deleterious side effects as not all the genes are known or functionally understood. A 
siRNA only down-regulates one specific gene, which would allow a therapy to have 
fewer undesired effects. 
 
 
4.3 Ets1 Increases Cell Proliferation but Cannot Rescue the Effects of MiR-1 
 
Upon co-transfection of Ets1 and miR-1 into A5 cells, Ets1 could not 
simultaneously increase proliferation that was suppressed by miR-1; however, in 
isolation it caused a dramatic increase in cell proliferation at 72 hours. From this, we 
can conclude Ets1 does act to increase cell proliferation. This study suggests that miR-1 
acts to decrease cell proliferation, but not by down-regulation of Ets1 because 
exogenous Ets1 did not rescue its effects.  The Ets1 construct did not contain a 3’UTR, 
so miR-1 would be unable to down-regulate exogenous Ets1, which rules out the 
conclusion that the exogenous Ets1 was degraded. This can be verified in future studies 
via western analyses of transfected cells Ets1. However, it is possible and likely that 
miR-1 regulates various targets responsible for decreasing proliferation; therefore, the 
amount of transfected exogenous Ets1 was not enough to rescue the effects resulting 
from down-regulation of other target genes. Rescuing the effects of miR-1 may require 
re-introduction of various target genes. 
 Future experimentation will be performed using different dosage amounts of 
miR-1 and Ets1 in transfections to confirm that neither one is over-expressed to a 
degree that will mask the effects of the other.  A simple way to validate this would be to 
compare protein expression in co-transfected cells with miR-1 transfected cells in an 
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attempt to identify the dosage of Ets1 required to restore endogenous levels of Ets1 to 
normal levels. Finally, in future studies, co-transfection of Ets1 and miR-1 will be 
repeated in attempt to determine if Ets1 rescues the effect of induced apoptosis by  
miR-1.  
Another approach to identifying the phenotypes associated with Ets1 is to utilize 
an Ets1 siRNA. The siRNA will preferentially knock down Ets1 expression. After 
transfecting this siRNA into the A5 cell line, phenotypes such as proliferation, apoptosis, 
migration, etc. can be assessed using similar experimentation as those previously used 
to determine phenotypes associated with miR-1. We have recently been attempting to 
knock down Ets1 with a siRNA; however, no knock-down is consistently observed. This 
may be because we have not yet found the optimal concentration of siRNA necessary 
for sufficient knockdown. We are continuing to trouble shoot and optimize 
experimentation.  
 
 4.4 Down-regulation of MiR-1 in Cutaneous SCC 
Our studies suggest that miR-1 is not down-regulated via chromatin silencing or 
methylation; however, there are other forms of transcriptional regulation to be 
considered.  
First, we can consider other forms of regulation of the miR-1 promoter region. 
There is the possibility that SNPs arise in the miR-1 promoter region of susceptible mice 
and SCC cells, which could possibly cause differential transcription factor binding. 
Previously, we sequenced the miR-1 promoter region in susceptible and resistant mice, 
and submitted the sequencing to the Transcriptional Element Search Software in order 
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to investigate potential differential transcription factor binding between miR-1 promoter 
region of the two strains of mice. The studies showed that the transcription factor, Gal4, 
may bind to the miR-1 promoter of resistant mice but not susceptible. Further, a study in 
lung cancer showed that miR-1 is regulated by the tumor suppressing C/EBPα 
transcription factor [25]. Future studies can focus on performing expression studies on 
these various transcription factors in order to determine if altered levels may correlate 
with the miR-1 down-regulation. If correlation exists, we can move to conduct functional 
studies such as reintroducing potential tumor suppressing transcription factors into SCC 
cell lines in order to rescue miR-1 expression. 
Similar to the approach of investigating miR-1 regulation via the promoter region, 
we could also consider miR-1 enhancer regions. In silico prediction programs such as 
http://enhancer.lbl.gov/ allows us to predict enhancer binding domains, and these 
domains could be sequenced in search of SNPs and differential binding of enhancer 
proteins. Studies suggest that alterations in distant enhancer regulatory regions could 
possibly contribute to increased susceptibility to carcinogenesis [59]. 
 
4.5 MicroRNA-1 and Ets1 as Potential Diagnostic Bio-markers and Therapeutics 
Our studies indicate that miR-1 may act as a SCC tumor suppressor, in part, via 
down-regulating Ets1 which could lead to potential future clinical applications. MiR-1 
levels could possibly be used as a biomarker. Studies indicate that some microRNAs in 
lung, breast, and ovarian cancer are found in circulation, in which case they could 
potentially serve as a prognostic or diagnostic factor dependent on a relatively simple 
procedure of measuring their expression in blood [60,61,62]. Down-regulation of miR-1 
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or up-regulation of Ets1 could correlate to the risk of eventually being diagnosed with 
SCC or serve as a prognostic factor for determining the severity of the disease.  
MiR-1 could also be used as a future SCC therapy. Current treatment for SCC is 
most commonly surgical removal which is often painful, costly, and even increases the 
risk of cosmetic disfigurement. If SCC does in fact metastasize, chemotherapeutic 
approaches to treatment are often associated with unwanted side effects and are not 
cell specific. MicroRNAs are enticing therapies as current research is being focused on 
developing adenoviruses that can be tissue and cancer cell specific [12]. Also, an 
argument can be made in advocating for the use of microRNAs over siRNAs as 
therapies in cancer because microRNAs have the potential to target many genes. If one 
microRNA targets multiple genes that are involved in the same mechanism of 
tumorigenesis, then the there should hypothetically be a greater effect.  Finally, 
minimally invasive injection or intranasal administration of these microRNA therapeutics 
are currently being investigated, which could eliminate the pain and discomfort 
associated with cosmetic removal [12].  
In conclusion, great advancements have been made in microRNA research over 
the past two decades, and they continue to do so. MicroRNAs have the potential to one 
day be effective, efficient treatment options for various cancers, including cutaneous 
SCC. Determining important microRNAs and their targets such as miR-1 and Ets1 in 
SCC could help enhance our control of this increasingly common disease and alleviate 
morbidity, and even in rare cases, mortality.  
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